Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease-Reference-Cited by-同舟云学术

Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease

Published:2022-08-25 Issue:9 Volume:2022 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Natale Patrizia¹²³,Palmer Suetonia C⁴,Jaure Allison²⁵,Hodson Elisabeth M²⁶,Ruospo Marinella¹,Cooper Tess E²⁶,Hahn Deirdre⁷,Saglimbene Valeria M¹²,Craig Jonathan C⁶⁸,Strippoli Giovanni FM¹²⁶

Affiliation:

1. Department of Emergency and Organ Transplantation; University of Bari; Bari Italy

2. Sydney School of Public Health; The University of Sydney; Sydney Australia

3. Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences; University of Foggia; Foggia Italy

4. Department of Medicine; University of Otago Christchurch; Christchurch New Zealand

5. Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia

6. Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia

7. Department of Nephrology; The Children's Hospital at Westmead; Westmead Australia

8. College of Medicine and Public Health; Flinders University; Adelaide Australia

Publisher

Wiley

Subject

Pharmacology (medical)

Reference244 articles.

1. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects;Akizawa;American Journal of Nephrology,2017

2. A 4 -week dose response study of the hypoxia inducible factor-prolyl hydroxylase inhibitor GSK1278863 in Japanese anemic haemodialysis subjects [abstract no: SA-PO819];Endo;Journal of the American Society of Nephrology,2015

3. Study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease clinicaltrials.gov/show/NCT02019719

4. Roxadustat for the treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis [abstract no: FR-PO1142];Akizawa;Journal of the American Society of Nephrology,2016

5. Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial;Akizawa;Advances in Therapy,2019

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease;NEJM Evidence;2024-08-27

2. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for treatment of anemia in chronic kidney disease: a systematic review and network meta-analysis;Frontiers in Pharmacology;2024-07-10

3. Evaluating the safety and efficacy of vadadustat for the treatment of anemia associated with chronic kidney disease;Expert Opinion on Pharmacotherapy;2024-06-12

4. Management of chronic kidney disease: The current novel and forgotten therapies;Journal of Clinical & Translational Endocrinology;2024-06

5. Anemia of Chronic Kidney Disease—A Narrative Review of Its Pathophysiology, Diagnosis, and Management;Biomedicines;2024-05-27